Renal Drugs
120 FDA-approved drugs
TheraRadar tracks 120 FDA-approved renal drugs from 63 companies across 13 drug classes, led by Fresenius Kabi, with 249 active clinical trials in the pipeline. Explore recent approvals, top companies, active trials by indication, and drug classes for Renal.
Renal Approvals by Year
1
'15
1
'16
3
'17
3
'18
3
'19
1
'20
4
'21
2
'22
4
'23
2
'24
3
'25
1
'26
Recent Renal Drug Approvals
SODIUM ZIRCONIUM CYCLOSILICATE
SODIUM ZIRCONIUM CYCLOSILICATE
2026-08-07
ALKEM LABS LTD
VOYXACT
SIBEPRENLIMAB-SZSI
VOYXACT is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN...
2025-11-25
OTSUKA
APRIL
IRON SUCROSE
IRON SUCROSE
iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD)...
2025-08-08
Viatris
Transferrin
VANRAFIA
ATRASENTAN HYDROCHLORIDE
VANRAFIA is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgA...
2025-04-02
Novartis
ETA receptor
VAFSEO
VADADUSTAT
anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least t...
2024-03-27
AKEBIA
HIF-prolyl-4-hydroxylases
VENXXIVA
TIOPRONIN
VENXXIVA is indicated, in combination with high fluid intake, alkali, and diet modification, for the...
2024-01-30
TORRENT
FABHALTA
IPTACOPAN HYDROCHLORIDE
adults with paroxysmal nocturnal hemoglobinuria (PNH)...
2023-12-05
Novartis
Factor B
FILSPARI
SPARSENTAN
FILSPARI is indicated to slow kidney function decline in adults with primary immunoglobulin A nephro...
2023-02-17
TRAVERE
AT1 receptorETA receptor
JESDUVROQ
DAPRODUSTAT
2023-02-01
GSK
TECHNETIUM TC 99M MERTIATIDE KIT
TECHNETIUM TC-99M MERTIATIDE KIT
2023-01-30
JUBILANT DRAXIMAGE
TERLIVAZ
TERLIPRESSIN ACETATE
TERLIVAZ is indicated to improve kidney function in adults with hepatorenal syndrome with rapid redu...
2022-09-14
MALLINCKRODT IRELAND
Vasopressin V1 receptorVasopressin V2 receptor
NEPHROSCAN
TECHNETIUM TC-99M SUCCIMER
use as an aid in the scintigraphic evaluation of renal parenchymal disorders in adult and pediatric ...
2022-02-18
THERAGNOSTICS
TARPEYO
BUDESONIDE
TARPEYO is indicated to reduce the loss of kidney function in adults with primary immunoglobulin A n...
2021-12-15
CALLIDITAS
Glucocorticoid receptor
KORSUVA
DIFELIKEFALIN ACETATE
moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hem...
2021-08-23
VIFOR INTL
Kappa opioid receptor
TIOPRONIN
TIOPRONIN
Tiopronin delayed-release tablets are indicated, in combination with high fluid intake, alkali, and ...
2021-04-26
Teva
FERUMOXYTOL
FERUMOXYTOL
iron deficiency anemia (IDA) in adult patients: • who have intolerance to oral iron or have had unsa...
2021-01-15
Novartis
MONOFERRIC
FERRIC DERISOMALTOSE
iron deficiency anemia (IDA) in adult patients: who have intolerance to oral iron or have had unsati...
2020-01-16
PHARMACOSMOS
Transferrin
TECHNETIUM TC99M MERTIATIDE KIT
TECHNETIUM TC-99M MERTIATIDE KIT
2019-07-12
Sun Pharma
THIOLA EC
TIOPRONIN
THIOLA EC is indicated, in combination with high fluid intake, alkali, and diet modification, for th...
2019-06-28
MISSION PHARMACAL
SEVELAMER HYDROCHLORIDE
SEVELAMER HYDROCHLORIDE
the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis...
2019-02-08
MACLEODS PHARMS
Showing the 20 most recent of 120 renal drugs. View all 120 →
Top Renal Companies
Renal Active Trials by Indication
249 active trials — the forward pipeline, not just approvals.
All competitive landscapes →Renal Drug Classes
Parenteral Iron Replacement 5
Reducing and Complexing Thiol 4
Potassium Binder 4
Vitamin D2 Analog 3
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor 1
Endothelin Receptor Antagonist 1
Vasopressin Receptor Agonist 1
Lead Chelator 1
Corticosteroid 1
Vasopressin V2 Receptor Antagonist 1
Renal at a Glance
- Total Drugs
- 120
- Companies
- 63
- Drug Classes
- 13
- Active Trials
- 249
- Latest Approval
- 2026-08-07